Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
2023-504552-10-01Phase 3Authorised
Phase 3, randomised, double-blind trial in acne papulopustulosa and acne vulgaris comparing Test clindamycin/tretinoin gel, Reference Acnatac gel and Vehicle control (3 arms). Primary endpoints: Percent change in inflammatory lesion count from baseline to week 12 and Percent change in total lesion count from baseline to week 12. Planned start May 2024; status: authorised.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on 2023-504552-10-01.